Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | PPIA | P62937 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967303 | 0.96 | CHRNA7 (0.57) | CHRNA7LMNAALDH1A1SORT1RAB9A | |
| SCHEMBL965249 | 0.95 | CHRNA7 (0.56) | CHRNA7LMNAALDH1A1SORT1RAB9A | |
| SCHEMBL964915 | 0.92 | CHRNA7 (0.54) | CHRNA7ALDH1A1SORT1RAB9AHTT | |
| SCHEMBL964143 | 0.85 | CHRNA7 (0.62) | CHRNA7LMNAALDH1A1RAB9ANPC1 | |
| SCHEMBL963651 | 0.84 | LMNA (0.63) | CHRNA7LMNARAB9ANPC1MEN1 | |
| SCHEMBL30352411 | 0.83 | ALDH1A1 (0.53) | CHRNA7LMNAALDH1A1RAB9AHTT | |
| SCHEMBL963949 | 0.83 | ALDH1A1 (0.53) | CHRNA7LMNAALDH1A1RAB9AHTT | |
| SCHEMBL963993 | 0.83 | LMNA (0.65) | CHRNA7LMNARAB9ANPC1MEN1 | |
| SCHEMBL968983 | 0.83 | LMNA (0.65) | CHRNA7LMNARAB9ANPC1MEN1 | |
| SCHEMBL965632 | 0.83 | LMNA (0.65) | CHRNA7LMNARAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471775-A1 | Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor | SUMITOMO CHEMICAL CO., LTD. (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2269986-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | PDCD2L, NOTUM, OXA1L | CHRNA7 2474/4885LMNA 4281/4885ALDH1A1 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.